TRIAMTERENE OR NOLATREXED FOR USE IN THE TREATMENT OF PHENYLKETONURIA

The present invention relates to a compound selected from the group consisting of nolatrexed, triamterene, sultopride and hydrastinine or a pharmaceutically acceptable salt thereof, preferably triamterene, nolatrexed or a pharmaceutically acceptable salt thereof, and to combination of said compounds...

Full description

Saved in:
Bibliographic Details
Main Authors REIG BOLANO, NURIA, INSA BORONAT, RAUL, SIGNORILE, LUCA, PERICOT MOHR, GAL.LA, FERRE FERRE, AILEEN, ESTEVA GRAS, SANTIAGO, HUERTAS GAMBIN, OSCAR
Format Patent
LanguageEnglish
French
Published 20.08.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to a compound selected from the group consisting of nolatrexed, triamterene, sultopride and hydrastinine or a pharmaceutically acceptable salt thereof, preferably triamterene, nolatrexed or a pharmaceutically acceptable salt thereof, and to combination of said compounds with other active ingredients, for use in the treatment and/or prevention of phenylketonuria, to the use of said compound or its combinations in the manufacture of a medicament for the treatment or prevention of said diseases and to a method of treating and/or preventing by administration of said compound or its combinations. La présente invention concerne un composé choisi dans le groupe constitué par le nolatrexed, le triamtérène, la sultopride et l'hydrastinine ou un sel pharmaceutiquement acceptable de celui-ci, de préférence le triamtérène, le nolatrexed ou un sel pharmaceutiquement acceptable de celui-ci, et la combinaison desdits composés avec d'autres principes actifs, destinée à être utilisée dans le traitement et/ou la prévention de la phénylcétonurie, l'utilisation dudit composé ou de ses combinaisons dans la fabrication d'un médicament pour le traitement ou la prévention desdites maladies et un procédé de traitement et/ou de prévention par administration dudit composé ou de ses combinaisons.
Bibliography:Application Number: CA20203129636